A Phase II Evaluation of Motesanib (AMG 706) in the Treatment of Persistent or Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Carcinomas: A Gynecologic Oncology Group Study

OBJECTIVES: Vascular endothelial growth factors (VEGF) and their receptors have a critical role in stimulating the growth of ovarian cancer cells. Motesanib is a small molecule inhibitor of multiple receptor tyrosine kinases including VEGF receptors 1-3, as well as c-KIT and platelet-derived growth...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Schilder, RJ, Sill, MW, Lankes, HA, Gold, MA, Mannel, RS, Modesitt, SC, Hanjani, P, Bonebrake, AJ, Sood, AK, Godwin, AK, Hu, W, Alpaugh, RK
Формат: Artigo
Язык:Inglês
Опубликовано: 2013
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3712785/
https://ncbi.nlm.nih.gov/pubmed/23321064
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2013.01.006
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы